Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P
Institut de Médecine Légale, Faculté de Médecine de Strasbourg, France.
Hum Exp Toxicol. 1995 Mar;14(3):294-8. doi: 10.1177/096032719501400310.
The first two observations of human poisoning involving the recently developed neuroleptic amisulpride are described. In both cases drug determination was performed using reversed-phase HPLC coupled with diode array detection. Case 1 was a nonfatal overdosage in which the ingestion of 3.0 g amisulpride induced an attack of seizures, then light coma with agitation, hyperthermia, mydriasis, minimal extrapyramidal features, tachycardia and slight prolongation of the QT interval; the blood concentration of amisulpride was 9.63 micrograms ml-1. Case 2 was a fatality attributed to amisulpride in which the measured blood concentration was 41.70 micrograms ml-1. Our results are discussed in the light of data previously reported on the toxicity of substituted benzamides.
本文描述了首例两起涉及最近研发的抗精神病药物氨磺必利的人体中毒观察案例。两起案例均采用反相高效液相色谱法结合二极管阵列检测进行药物测定。案例1为非致命性过量用药，摄入3.0克氨磺必利引发癫痫发作，随后出现轻度昏迷伴躁动、高热、瞳孔散大、轻微锥体外系症状、心动过速以及QT间期轻度延长；氨磺必利血药浓度为9.63微克/毫升。案例2为氨磺必利致死案例，测得血药浓度为41.70微克/毫升。我们结合先前报道的关于取代苯甲酰胺毒性的数据对结果进行了讨论。
